表紙
市場調查報告書

急性腎功能衰竭治療藥:機會評估,流行病學研究,市場動態,開發平台分析

Acute Kidney Injury Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019

出版商 GervanoRA Data Services LLP 商品編碼 916194
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
急性腎功能衰竭治療藥:機會評估,流行病學研究,市場動態,開發平台分析 Acute Kidney Injury Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019
出版日期: 2019年11月08日內容資訊: 英文 140 Pages
簡介

本報告提供全球急性腎功能衰竭治療藥市場相關調查分析,現在、未來的機會為焦點,市場價值,專利分析,市場佔有率等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 疾病概要

  • 疾病定義與症狀
  • 病因與分類
  • 疾病診斷
  • 治療流程和指南
  • 流行病學研究
  • 流行病學預測

第4章 市場概要

  • 交易 (M&A,聯盟)
  • 專利分析 (失效,學名藥)

第5章 開發平台分析

  • 開發平台分析:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各藥物分類
  • 開發平台分析:各作用機制
  • 開發平台分析:各大學、機關

第6章 臨床階段的開發平台藥物的說明與開發里程碑

  • 階段3開發平台藥物的說明與開發里程碑
  • 階段2開發平台藥物的說明與開發里程碑
  • 階段1開發平台藥物的說明與開發里程碑

第7章 核准計劃的預測

  • 調查手法
  • 核准計劃的預測

第8章 臨床實驗摘要

  • 分析:各臨床實驗結果
  • 進行中的臨床實驗摘要
  • 計劃中臨床實驗摘要
  • 最近完成的臨床實驗摘要
  • 中止的臨床實驗

第9章 機會評估和競爭基準

第10章 現在、未來的競爭情形

  • 新興企業
  • 現有企業

第11章 簡稱

目錄
Product Code: GERPH834

GervanoRA's pipeline analysis and opportunity assessment report "Acute Kidney Failure Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019" analyzed and assessed Acute Kidney Failure pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Acute Kidney Failure industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Growth Opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader in the Acute Kidney Failure Disease Space.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2 KEY EVENTS IN THE COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET OVERVIEW

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 MOLECULES
    • 5.1.2. PHASE 2 MOLECULES
    • 5.1.3. PHASE 1 MOLECULES
    • 5.1.4. PRECLINICAL MOLECULES
    • 5.1.5. EARLY R&D STAGE MOLECULES
    • 5.1.6. INACTIVE AND DISCONTINUED MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE MOLECULES BY UNIVERSITY AND INSTITUTES - IN LICENSING AND OUT LICENSING OPPORTUNITIES

6. CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.2. PHASE 2 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.3. PHASE 1 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

7. ESTIMATED APPROVAL TIMELINES

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. CLINICAL TRIALS SUMMARY

  • 8.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 8.1.1. KEY PHASE 2 CLINICAL TRIAL RESULTS
  • 8.2. ONGOING CLINICAL TRIALS SUMMARY
    • 8.2.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 8.2.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 8.2.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 8.3. PLANNED CLINICAL TRIAL SUMMARY
    • 8.3.1. PLANNED PHASE 3 CLINICAL TRIALS
    • 8.3.2. PLANNED PHASE 2 CLINICAL TRIALS
    • 8.3.3. PLANNED PHASE 1 CLINICAL TRIALS
  • 8.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 8.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    • 8.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    • 8.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
  • 8.5. WITHDRAWN AND TERMINATED CLINICAL TRIALS

9. OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING

  • 9.1. EXTERNAL DEPENDENCIES
  • 9.2. PIPELINE PORTFOLIO
  • 9.3. EXPECTED MARKET ENTRIES
  • 9.4. PATENTS AND EXCLUSIVITY
  • 9.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 9.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 9.7. COMPANY DEVELOPMENTS

10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 10.1. KEY EMERGING COMPANIES
    • 10.1.1. KEY EMERGING COMPANY PROFILES
  • 10.2. EMERGING COMPANIES
    • 10.2.1. EMERGING COMPANY PROFILES

11. ABBREVIATIONS

LIST OF TABLES:

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: SOME RECENT FUNDING RECEIVED FOR AKI RESEARCH IN 2019
  • TABLE 03: ACUTE KIDNEY INJURY EPIDEMIOLOGY (2018) AND FORECAST (2019-2025), IN MILLION
  • TABLE 04: TOP 10 DEALS IN THE ACUTE KIDNEY INJURY DISEASE AREA, RANKED BY DEAL AMOUNT
  • TABLE 05: FINANCING DEALS IN ACUTE KIDNEY INJURY DISEASE AREA
  • TABLE 06: PATENT PORTFOLIO OF ANGION AKI MOLECULE
  • TABLE 07: PATENT PORTFOLIO OF AM-PHARMA AKI MOLECULE
  • TABLE 08: PATENT PORTFOLIO OF SULFATEQ AKI MOLECULE
  • TABLE 09: PHASE 3 MOLECULES IN ACUTE KIDNEY FAILURE DRUG PIPELINE
  • TABLE 10: PHASE 2 MOLECULES IN ACUTE KIDNEY FAILURE DRUG PIPELINE
  • TABLE 11: PHASE 1 MOLECULES IN ACUTE KIDNEY FAILURE DRUG PIPELINE
  • TABLE 12: PRECLINICAL MOLECULES IN ACUTE KIDNEY FAILURE DRUG PIPELINE
  • TABLE 13: INACTIVE AND DISCONTINUED MOLECULES IN ACUTE KIDNEY FAILURE DRUG PIPELINE
  • TABLE 14: DRUG CLASSES OF AKI PIPELINE MOLECULES
  • TABLE 15: UNIVERSITY AND INSTITUTE'S PIPELINE MOLECULES FOR ACUTE KIDNEY FAILURE
  • TABLE 16: ESTIMATED APPROVAL TIMELINES OF KEY ACUTE KIDNEY FAILURE PIPELINE DRUGS
  • TABLE 17: AM-PHARMA'S STOP-AKI PHASE 2 TRIAL DESIGN
  • TABLE 18: QUARK PHARMACEUTICAL'S QRK209 PHASE 2 TRIAL DESIGN
  • TABLE 19: PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 20: PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 21: PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 22: PLANNED PHASE 2 CLINICAL TRIALS FOR ACUTE KIDNEY FAILURE
  • TABLE 23: PLANNED PHASE 1 CLINICAL TRIALS FOR ACUTE KIDENY FAILURE
  • TABLE 24: QUARK PHARMACEUTICALS' COMPLETED PHASE 3 CLINICAL TRIAL DESIGN
  • TABLE 25: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS FOR ACUTE KIDNEY FAILURE
  • TABLE 26: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS FOR ACUTE KIDNEY FAILURE
  • TABLE 27: TERMINATED CLINICAL TRIALS FOR ACUTE KIDNEY FAILURE
  • TABLE 28: PIPELINE PORTFOLIO OF QUARK PHARMACEUTICALS
  • TABLE 29: KEY US PATENTS OF QUARK PHARMACEUTICALS
  • TABLE 30: REGULATORY ALLOWANCES RECEIVED BY EMERGING COMPANIES
  • TABLE 31: QUARK'S PIPELINE ASSETS WITH RESPECT TO KIDNEY DISEASES
  • TABLE 32: QUARK'S PIPELINE ASSETS WITH RESPECT TO EYE DISEASES
  • TABLE 33: QUARK'S PIPELINE ASSETS, PRECLINICAL AND DISCOVERY PROGRAMS
  • TABLE 34: QUARK'S TECHNOLOGICAL ASSETS
  • TABLE 35: QUARK'S ISSUED PATENT PROFILE
  • TABLE 36: RESEARCH AND DEVELOPMENT ACTIVITIES OF QUARK
  • TABLE 37: RECENT DEVELOPMENTS OF QUARK
  • TABLE 38: PARTNERING ACTIVITIES OF QUARK
  • TABLE 39: MILESTONES ACHIEVED OF QUARK
  • TABLE 40: ANGION'S INDICATIONS TARGETED BY ANG-3777
  • TABLE 41: ANGION'S PRECLINICAL PROGRAMS
  • TABLE 42: ANGION'S ISSUED PATENT PROFILE
  • TABLE 43: ALLOKSYS'S PIPELINE ASSETS
  • TABLE 44: RESEARCH AND DEVELOPMENT ACTIVITIES OF ALLOKSYS
  • TABLE 45: ATOX BIO PRODUCT PIPELINE
  • TABLE 46: ATOX BIO RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 47: ATOX BIO ACHIEVEMENTS
  • TABLE 48: AM-PHARMA'S PIPELINE ASSETS
  • TABLE 49: RESEARCH AND DEVELOPMENT ACTIVITIES OF AM-PHARMA
  • TABLE 50: PARTNERING ACTIVITIES OF AM-PHARMA
  • TABLE 51: RECENT DEVELOPMENTS OF AM-PHARMA
  • TABLE 52: EBI'S CLINICAL PROGRAMS FOR EA-230
  • TABLE 53: SENTIEN'S CURRENT PROGRAMS FOR SBI-101
  • TABLE 54: RESEARCH AND DEVELOPMENT ACTIVITIES OF SENTIEN
  • TABLE 55: RECENT DEVELOPMENTS OF SENTIEN
  • TABLE 56: CYPRALIS'S CLINICAL PROGRAMS FOR CC-4066
  • TABLE 57: RECENT DEVELOPMENTS OF CYPRALIS
  • TABLE 58: ARCH BIOPARTNER'S PIPELINE ASSETS
  • TABLE 59: PATENT PORTFOLIO OF ARCH BIOPARTNER
  • TABLE 60: RESEARCH AND DEVELOPMENT ACTIVITIES OF ARCH BIOPARTNER
  • TABLE 61: PARTNERING ACTIVITIES OF ARCH BIOPARTNER
  • TABLE 62: RECENT DEVELOPMENTS OF ARCH BIOPARTNER
  • TABLE 63: SPHERIUM'S PIPELINE ASSETS
  • TABLE 64: R&D ACTIVITIES OF SPHERIUM
  • TABLE 65: RECENT DEVELOPMENTS OF SPHERIUM
  • TABLE 66: SULFATEQ'S PIPELINE ASSETS
  • TABLE 67: PATENT PORTFOLIO OF SULFATEQ
  • TABLE 68: RECENT DEVELOPMENTS OF SULFATEQ
  • TABLE 69: GUARD THERAPEUTIC'S ROSGARD CLINICAL DEVELOPMENT
  • TABLE 70: GUARD THERAPEUTICS' RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 71: REDX PHARMA PRODUCT PORTFOLIO
  • TABLE 72: REDX PHARMA PATENT PORTFOLIO
  • TABLE 73: REDX PHARMA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 74: REDX PHARMA'S RECENT DEVELOPMENTS
  • TABLE 75: REDX PHARMA'S PARTNERING ACTIVITIES
  • TABLE 76: REDX PHARMA'S ACHIEVED AWARDS
  • TABLE 77: SLIVER CREEK PHARMACEUTICALS PRODUCT PORTFOLIO

LIST OF FIGURES:

  • FIGURE 01: KEY EVENTS IN ACUTE KIDNEY INJURY DISEASE AREA
  • FIGURE 02: ETIOLOGY OF ACUTE RENAL FAILURE
  • FIGURE 03: ACUTE KIDNEY INJURY EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 04: ACUTE KIDNEY INJURY DISEASE DEALS, BY DEAL TYPE
  • FIGURE 05: ACUTE KIDNEY FAILURE PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 06: ACUTE KIDNEY FAILURE DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 07: SPLIT UP BY HSD WITH RESPECT TO INJECTABLE ROUTE
  • FIGURE 08: AKI PIPELINE MOLECULES, DRUG CLASS SPLIT UP
  • FIGURE 09: PRIMARY ENDPOINT COMPARISON (ALL GROUPS), MEDIAN AUC 1-7 ECC
  • FIGURE 10: COMPARISON FATAL AE(S) AND NON-FATAL SAE(S) AMONG FOUR DOSAGE GROUPS
  • FIGURE 11: PIPELINE PORTFOLIO OF TOP 10 EMERGING COMPANIES
  • FIGURE 12: RANKING OF THE TOP 10 EMERGING COMPANIES BASED ON THE EXTERNAL FUNDING RECEIVED
  • FIGURE 13: ANTICIPATED FIRST MARKET ENTRIES IN THE US
  • FIGURE 14: RANKING OF TOP 10 EMERGING COMPANIES BASED ON THEIR PATENT ASSET
  • FIGURE 15: TIMELINE OF PATENT EXPIRIES IRRESPECTIVE OF AKI DISEASE AREA
  • FIGURE 16: TIMELINE OF PATENT EXPIRIES IN AKI DISEASE AREA
  • FIGURE 17: RANKING OF TOP 10 EMERGING COMPANIES BASED ON THE PARTNERING ACTIVITIES
  • FIGURE 18: KEY TITLES ACHIEVED BY THE TOP EMERGING COMPANIES